SeeThruEquity Initiates Research Coverage on Cardax, Inc. with a Target Price of $1.00

New York, NY / ACCESSWIRE / October 6, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Cardax, Inc. CDXI, Cardax is a development stage, life sciences company focused on introducing nutraceutical and pharmaceutical products aimed at reducing inflammation and oxidative stress.

“We are intrigued by the company's development of nature-identical astaxanthin which reduces inflammation without the usual side effects of NSAIDs or other currently available anti-inflammatory treatments,” stated Ajay Tandon, CEO of SeeThruEquity. “With a focus on the source of inflammation, the company has a strong pipeline of drug development opportunities. We are initiating coverage with a target price of $1.00.”

Additional investment highlights are as follows:

Unique way to invest in growth of astaxanthin

Cardax has developed a unique way to produce nature-identical astaxanthin, a substance with many potential applications that is proven to reduce inflammation at its source, without the harmful side effects of common anti-inflammatory and pain relief medications. This combination opens up a range of possibilities for Cardax, as it prepares to bring to market a nutraceutical product in the short-term, and prepares to develop clinical trials to determine whether it can also use its technology to develop astaxanthin-based pharmaceuticals and over-the-counter anti-inflammatory drugs.

Strong strategic alliances to drive growth

Cardax has struck deep partnerships with two key industry participants – BASF and Capsugel – which should provide revenue opportunities for the company in the near term. Additionally, we view these alliances as further validation of the prospects for astaxanthin. BASF, the world's largest chemical company, has licensed exclusive rights from Cardax for the commercialization of nature-identical, synthetic astaxanthin, ASTX-1, as a nutraceutical. With lower regulatory restrictions on nutraceuticals, the product approval and introduction should move much faster than a pharmaceutical drug, allowing BASF and Cardax to have a product available for sale in mid-2015, in our estimation. The Cardax-BASF collaboration enables efficient, scalable, and economical path to make astaxanthin available to mass markets at a scale and cost that should not be able to be matched by low-volume agricultural producers. We are also encouraged by the Capsugel partnership, in which Cardax and Capsugel will work together with a third party to bring a new oral capsule version of astaxanthin to market.

Strong pipeline of drug development opportunities

Cardax's therapies focus on the source of inflammation, which has potential applications for the treatment of many diseases. After the company launches its commercial products for the nutraceutical market, we expect Cardax to pursue three to five low-risk phase 2 clinical trials to prove efficacy of astaxanthin for the treatment of inflammation-related disorders. We expect that Cardax may seek a partner for some indications and that the company will target osteoarthritis, metabolic syndrome, liver disease, and cardiovascular disease. Each of these indications represents a multi-billion dollar market opportunity, and we view positive clinical trial results in the future as a possible significant catalyst for the company.

The report is available here: CDXI Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will also be available on these platforms.

Please review important disclosures on our website at http://www.seethruequity.com/.

About Cardax, Inc.

Cardax, Inc. is a development stage life sciences company that devotes substantially all of its efforts to developing nutraceutical and pharmaceutical products that provide many of the anti-inflammatory benefits of steroids or NSAIDS, but with exceptional safety profiles, as conferred by U.S. Food and Drug Administration (“FDA”) Generally Recognized as Safe (“GRAS”) designation at certain doses. Cardax is preparing proprietary nature-identical products and related derivatives by total synthesis to provide scalable, pure, and economical therapies for diseases where inflammation and oxidative stress are strongly implicated, including, but not limited to, osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease. The initial primary focus of Cardax is its astaxanthin technologies. Astaxanthin is a powerful and safe naturally occurring anti-inflammatory and anti-oxidant without the adverse side effects typical of anti-inflammatory treatments using steroids or NSAIDS, including immune system suppression, liver damage, cardiovascular disease risk, and gastrointestinal bleeding.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit http://www.seethruequity.com/.

Contact:

Ajay Tandon
SeeThruEquity
(646) 495-0939

Source: SeeThruEquity